logo
Share SHARE
FONT-SIZE Plus   Neg

Pre-market Movers For May 11 (JPM, JWN, NVDA, GKNT, ARNA, WWWW)

Gainers:

NVIDIA Corp. (NVDA) is up 7 percent to $13.34. The company's first quarter profit plunged from the year-ago quarter. Revenue declined from the prior year period, but was above Wall Street view. Meanwhile, the company guided second quarter revenue above consensus.

Arena Pharmaceuticals, Inc. (ARNA) is jumping 92 percent to $7.05. The company announced that the FDA Endocrinologic and Metabolic Drugs Advisory Committee has recommended the approval of its investigational drug candidate lorcaserin intended for weight management.

Decliners:

JPMorgan Chase & Co. (JPM) is down 8 percent to $37.46. The company disclosed that since March 31, 2012, its Chief Investment Office has had hefty mark-to-market losses in its synthetic credit portfolio that has proved to be more riskier than expected. The company currently estimates its Corporate business, within the Corporate/Private Equity segment, to incur a net loss in its second quarter of about $800 million, which excludes Private Equity results and litigation expense.

Nordstrom, Inc. (JWN) is declining 4 percent to $51.55. The company's first quarter profit increased from the previous year period, but missed Wall Street view. Net sales improved 13.7 percent, while same-store sales increased 8.5 percent. Meanwhile, the company expects fiscal 2012 earnings per share below analysts' estimate.

Web.com Group, Inc. (WWWW) is falling more than 2 percent to $15.16. The company announced the pricing of public offering of 8 million shares of its common stock by certain selling stockholders at $15.25 per share.

Trading halt:

Trading in shares of Geeknet, Inc. (GKNT) was halted. The company announced its plan to explore strategic alternatives with respect to its online media business, including the SourceForge, Slashdot and Freecode websites.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT